| Literature DB >> 32843339 |
Catherine L Moyes1, Duncan K Athinya2, Tara Seethaler3, Katherine E Battle4, Marianne Sinka5, Melinda P Hadi6, Janet Hemingway7, Michael Coleman8, Penelope A Hancock1.
Abstract
Malaria vector control may be compromised by resistance to insecticides in vector populations. Actions to mitigate against resistance rely on surveillance using standard susceptibility tests, but there are large gaps in the monitoring data across Africa. Using a published geostatistical ensemble model, we have generated maps that bridge these gaps and consider the likelihood that resistance exceeds recommended thresholds. Our results show that this model provides more accurate next-year predictions than two simpler approaches. We have used the model to generate district-level maps for the probability that pyrethroid resistance in Anopheles gambiae s.l. exceeds the World Health Organization thresholds for susceptibility and confirmed resistance. In addition, we have mapped the three criteria for the deployment of piperonyl butoxide-treated nets that mitigate against the effects of metabolic resistance to pyrethroids. This includes a critical review of the evidence for presence of cytochrome P450-mediated metabolic resistance mechanisms across Africa. The maps for pyrethroid resistance are available on the IR Mapper website, where they can be viewed alongside the latest survey data.Entities:
Keywords: insecticide resistance; insecticide resistance management; malaria control; metabolic resistance; pyrethroid
Mesh:
Substances:
Year: 2020 PMID: 32843339 PMCID: PMC7486715 DOI: 10.1073/pnas.2006781117
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205
Recommendations regarding insecticide choice for LLINs and IRS
| 1. What is the primary intervention currently in use? | 2: What is the resistance status (susceptibility test result)? | |||
| Pyrethroid resistant (<90% mortality) | ||||
| Susceptible (>98% mortality) | No cytochrome P450-mediated resistance or no data (<10% increase in mortality with PBO) | Cytochrome P450-mediated resistance (≥10% increase in mortality with PBO) | ||
| (10–80% mortality without PBO) | (Mortality without PBO not 10–80%) | |||
| LLINs | Continue monitoring using susceptibility tests and, if cases are increasing, ensure timely replacement of worn-out nets and assure the quality and extent of LLIN coverage. | In addition to LLINs, introduce focal IRS in annual rotations, at least in areas of greatest concern, and use nonpyrethroid active ingredients when they become available, providing this does not compromise coverage. | Consider switching to PBO-treated LLINs. and/or introducing focal IRS in annual rotations, at least in areas of greatest concern, and using nonpyrethroid active ingredients, providing this does not compromise coverage. | Introduce focal IRS in annual rotations, at least in areas of greatest concern, and use nonpyrethroid active ingredients, providing this does not compromise coverage. |
| IRS | Preemptive rotation of insecticide classes with confirmed susceptibility. | Switch away from current insecticide and rotate alternative compounds. | ||
This is an abridged summary of the recommendations in tables 4 and 5 of the Global Plan for IRM and accompanying text, the thresholds defined in the WHO’s Test Procedures for Insecticide Resistance Monitoring, and the recommendations outlined in the Conditions for Deployment of PBO-treated Nets (3, 10, 12). The recommendations linked to the presence of kdr mechanisms have been excluded for reasons of brevity and because these are not materially different from “resistance without mechanism data” or “no cytochrome P450-mediated resistance.” The threshold values for susceptibility test results are given in parentheses.
Fig. 1.Gaps in the available insecticide resistance surveillance data from standard WHO and CDC tests using the An. gambiae complex and An. funestus subgroup. (A) Districts with susceptibility test (bioassay) results for 2015 to 2017 from a published susceptibility test dataset that collated data from routine monitoring by agencies such as the President’s Malaria Initiative (PMI) and from research groups in Africa and was subject to rigorous quality-assurance processes (15). Ninety-four percent (3,136/3,323) of malaria-endemic second-order administrative divisions do not have any data for insecticide resistance in this year and 89% (2,962/3,323) do not have any data in this year or the two preceding years. (B) Data shown on the WHO Malaria Threats website for the years 2015 to 2019 (accessed 9 December 2019) (16). (C) Data shown on the IR Mapper website for the years 2015 to 2019 (accessed 9 December 2019) obtained from published articles and PMI surveillance (17).
Fig. 2.District-level deltamethrin resistance in local An. gambiae s.l. populations. (A) Predicted mean susceptibility test mortality for each district in 2017. (B) Predicted minimum susceptibility test mortality for each district in 2017. (C) Probability that mean susceptibility test mortality for the district is >98%, the definition of a “susceptible” population. (D) Probability that mean susceptibility test mortality for the district is <90%, the definition of a “resistant” population (22).
Fig. 3.The respective distributions of An.gambiae s.l. and An. funestus. (A) The predicted distribution of An. gambiae s.l. taken from Wiebe et al. (22). (B) The predicted distribution of An. funestus taken from Wiebe et al. (22). (C) The overlap in predicted presence (binary values) of An.gambiae s.l. and An. funestus.
Fig. 4.The probability of meeting the criteria for the deployment of PBO-treated nets. (A) The predicted probability that the mean mortality for a district is 10 to 80%. (B) Districts with surveillance data from paired standard susceptibility tests using a pyrethroid with and without the synergist PBO. (C) Plot of surveillance data from paired standard susceptibility tests using a pyrethroid with and without the synergist PBO showing the full variation in the results and key thresholds defined in WHO guidelines.
Comparing the accuracy of next-year predictions
| Next year | RMSE | ||
| Ensemble model fit to surveillance data up to preceding year | Mean value of surveillance data from preceding year | Minimum value of surveillance data from preceding year | |
| Data available in preceding year | |||
| West region | |||
| 2015 | 0.232 ( | 0.386 ( | |
| 2016 | 0.276 ( | 0.309 ( | |
| 2017 | 0.384 ( | 0.50 ( | |
| East region | |||
| 2015 | 0.194 ( | 0.301 ( | |
| 2016 | 0.281 ( | 0.298 ( | |
| 2017 | 0.323 ( | 0.395 ( | |
| Data not available in preceding year | |||
| West region | |||
| 2015 | 0.315 ( | No data | No data |
| 2016 | 0.327 ( | No data | No data |
| 2017 | No data | No data | No data |
| East region | |||
| 2015 | 0.218 ( | No data | No data |
| 2016 | 0.270 ( | No data | No data |
| 2017 | 0.289 ( | No data | No data |
The RMSE of predicted and observed next-year resistance where all data obtained after the given year were withheld from the prediction methods. A lower RMSE indicates a more accurate prediction. Observed datasets consisted of all pyrethroid susceptibility test results (performed using α-cypermethrin, deltamethrin, permethrin, and λ-cyhalothrin) from the next year for districts where test results for the preceding year were available. n is the number of withheld data points. The RMSE values shown in bold indicate the best-performing model for each year where multiple options are presented.